AIM ImmunoTech

AIM

Market cap $6.93M

CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the Company for what management believes could be a pivotal period in its evolution as a clinical-stage oncology company.

LOS ANGELES--(BUSINESS WIRE)-- #aimsportsgroup--AIM Sports Group hosted the SoCal Cup ‘Showcase' tournament, one of the nation's leading tournament series for youth club volleyball, at the Los Angeles Convention Center (LACC) this past Father's Day weekend.The Showcase, operated by AIM Sports Group, drew more than 550 elite boys club volleyball teams of various age groups (12U through 18U) from across the nation and wowed visitors with a weekend experience of the highest level of competition, development, collegi.

OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026.

Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

GUANGZHOU, China , June 17, 2026 (GLOBE NEWSWIRE) -- As global capital, industrial transformation, and cross border trade realign around new growth corridors, AIM Talks China 2026 convened investors, policymakers, and business leaders in one of China's most dynamic economic ecosystems, serving as a focused platform for international dialogue, strategic networking, and high impact business engagement. The opening ceremony of AIM Talks China 2026 took place on 17 June 2026 in Tianhe CBD, Guangzhou, marking the launch of a high level platform that brings together investors, policymakers, business leaders, and institutional stakeholders from China, the UAE, and international markets.

OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained compliance with NYSE American's continued listing standards related to stockholders' equity.

As a pilot participant, Infosys contributed to shaping the CMMI AI Maturity (AIM) framework – bringing enterprise-scale AI practices, governance models, and real-world deployment insights – powered by Infosys Topaz AI offerings – to define industry benchmarks Among the first organizations globally to complete the CMMI AI Maturity Pilot Assessment BENGALURU, India, June 11, 2026 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in AI-first business consulting and technology services, today announced that it has successfully completed and contributed to the CMMI AI Maturity (AIM) Framework and Pilot Assessment, conducted by CMMI® Institute, a global leader in helping organizations reduce risk, boost performance and build capability. Through this collaboration, Infosys assisted with the advancement of the CMMI AIM framework – contributing deep enterprise-scale perspectives on AI governance, responsible deployment, and outcome-driven practices that helped define how AI maturity is assessed and operationalized across global organizations.

OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting placement agent commissions and other offering expenses.